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Abstract
Cervical cancer is considered as an important malignancy among women worldwide. Currently-used treatments of
cervical cancer are reported to be cytotoxic for patients. Moreover, these therapies have shown some side effects
which can negatively affect the lives of women suffering from this cancer. Therefore, there is need for anti-tumor
agents that are less toxic than common therapeutic drugs. Besides, applying agents for preventing or reducing the
side effects of cervical cancer therapies can be effective in improving the life quality of cervical cancer patients.
Studies have shown that probiotics have several effects on biological processes. One of the most prominent
aspects in which probiotics play a role is in the field of cancer. There are multiple studies which have focused on
the functions of probiotics in diagnosis, prevention, or treatment of cancer. Besides their direct anti-tumor activities,
probiotics can be used as an additional agent for enhancing or modulating other diagnostic and therapeutic
methods. Herein, the effects of probiotics on cervical cancer cells are discussed, which may be useful in the
prevention and treatment of this cancer. We review the studies concerned with the roles of probiotics in
modulating and reducing the gastrointestinal adverse effects caused by cervical cancer therapies. Furthermore, we
cover the investigations focusing on the combination of probiotics with other drugs for diagnosis or treatment of
cervical cancer.
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Background
There are thousands of bacterial species in the human
body, which provide and maintain the health of their
host [1, 2]. Nine percentage of microbial species are lo-
cated in the urogenital tract. Thus, there should be a
balancing connection between the immune system of
host and microbiota that exist in urogenital tract [1, 3,
4]. Disruptions in this balance may lead to cervical can-
cer by allowing infectious agents to grow in this area.
Currently-used chemotherapeutic drugs can result in
cytotoxic effects in patients suffering from cervical can-
cer. Besides, there are side effects caused by therapies
which are unavoidable [5]. Therefore, there is need for
anti-tumor agents that are non-toxic or cause less tox-
icity than other therapeutic agents. Also, applying drugs
for preventing or reducing the side effects of cervical
cancer treatment would be effective in enhancing the life
quality of cervical cancer patients [6].
Herein, the effects of probiotics on cervical cancer
cells which may be useful in the prevention and/or treat-
ment of this cancer are discussed. We review the studies
concerned with the roles of probiotics in modulating
and reducing the gastrointestinal adverse effects caused
by cervical cancer therapies. Furthermore, we cover the
investigations focusing on the combination of probiotics
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with other drugs for diagnosis or treatment of cervical
cancer.
Cervical cancer
Epidemiology
Cervical cancer is considered a global health concern
since it is the fourth common malignancy among
women worldwide [7]. Cervical cancer comprises 4% of
all cancers that are diagnosed all around the world [8].
Based on morphological characteristics, there are three
main subtypes of cervical cancer, including squamous
cell carcinoma, adenocarcinoma, and adenosquamous
carcinoma. All of these subtypes have the same one-year
net survival rate of 85% [9]. Adenocarcinoma and squa-
mous cell carcinoma, the two most frequent subtypes,
are responsible for nearly 25 and 70% of cervical cancer,
respectively [10, 11]. In addition, there are metabolic dis-
turbances in women with polycystic ovarian syndrome
[12, 13], which may increase the risk of cervical cancer.
Noteworthy, incidence rates and deaths of cervical can-
cer have been progressively reduced in the well-
developed countries because of HPV vaccination and
cancer screening programs [14, 15].
Risk factors
One of the well-studied risk factors of cervical cancer is
HPV chronic infection. Besides, there are other factors
implied to raise the risk of this cancer including smok-
ing, co-infection with type 2 herpes simplex, co-infection
with human immunodeficiency virus, high parity, and
consumption of oral contraceptives for a long time [16,
17]. Some risk factors of cervical cancer are related to
acquiring HPV infection or inefficient response of the
immune system to HPV infection such as sexual debut
at early ages, high-risk sexual partners, multiple sexual
partners, immunosuppression, history of sexually trans-
mitted infection (STI), and history of HPV-related vulvar
or vaginal dysplasia [11].
Prevention
HPV vaccination and screening of cervical cancer can be
applied to prevent this disease. HPV, which is the most
common STI globally, accounts for virtually all (99.7%)
of the cervical cancer cases [18]. More than two-thirds
of cervical cancers and precancerous lesions are caused
by two HPV types that are type 16 and 18 [19, 20].
There are two approved vaccines for HPV, including bi-
valent vaccine and quadrivalent vaccine. The former one
is against 16 and 18 types of HPV types and quadrivalent
vaccine (against HPV types 6, 11, 16, and 18) [21]. Pre-
dictions show that the incidence of cervical cancer will
decrease up to 83% by a 90% coverage of vaccine [22].
The pre-cancerous condition can be detected and
treated by a secondary prevention method called cervical
cancer screening, which is helpful in malignancy preven-
tion [23]. In high-resource countries, early diagnosis and
treatment of precancerous lesions can prevent up to 80%
of cervical cancer [24]. Cytology is the most frequent
tool for cervical cancer screening which is used in devel-
oped countries [23]. In patients whose screening has
shown premalignant cervical lesions such as cervical
intraepithelial neoplasia, colposcopy is done to confirm
the finding [25]. In low-resource countries, a feasible
see-and treat method is visual inspection with acetic acid
(VIA) or visual inspection with Lugol’s iodine (VILI)
[26]. However, coverage of screening programs is still
low despite the increase in the availability of them [23].
Clinical presentation and diagnosis
Cervical cancer does not usually show any symptoms in
its early stages [27]. Post-coital vaginal bleeding, abnor-
mal vaginal bleeding, and malodorous vaginal discharge
are symptoms of this cancer [28, 29]. Passages of urine
and feces through the vagina are symptoms for an inva-
sion of the bladder and rectum, respectively [30, 31]. A
pelvic examination and cervical cytology, as well as
visualization of the cervix and vaginal mucosa by a
speculum, are needed when a woman presented with
cervical cancer symptoms [11]. However, the cervix may
look normal in observations when the cancer is micro-
invasive or occurred in the endocervical canal [11].
There are possibly palpable swollen and hardened lymph
nodes in inguinal and supraclavicular regions in patients
with the advanced-stage disease [11]. In distant metasta-
sis, positron emission tomography (PET)-computed
tomography and fluoro-2-deoxy-D-glucose PET (FDG-
PET) are two efficient methods for diagnosis [32].
Treatment
Currently, cervical cancer management is dependent on
a multidisciplinary team approach [33]. In the early
stages of the disease, there are multiple treating ap-
proaches that can be used, including surgery, radiation,
neoadjuvant chemotherapy, and fertility preservation
surgery [33]. The standard treatment for patients suffer-
ing from locally advanced cervical cancer is concurrent
chemoradiation (CCRT) in which cisplatin is used alone
or in combination with other drugs [33]. In nearly 30–
40% of cases, there is a lack of complete response [33].
Bevacizumab is an inhibitor of vascular endothelial
growth factor [34]. In the recurrent or metastatic form
of the disease, bevacizumab administration along with
chemotherapy has linked to enhanced survival [33].
Different treating options are available for managing
metastatic patients who suffer from lung metastasis,
bone metastasis, solitary brain metastasis, or multiple
brain metastases. These treating approaches include
chemotherapy and surgery, chemotherapy and bone
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irradiation, craniotomy or stereotactic radiosurgery com-
bined with radiotherapy, and chemotherapy and pallia-
tive brain radiation, respectively [32]. Moreover, CCRT
followed by chemotherapy are helpful in lymph meta-
static patients [32]. Investigations have provided promis-
ing findings of novel therapeutic methods such as
inhibitors of the immune checkpoint, inhibitors of tyro-
sine kinase, and targeted therapy with anti-angiogenesis
drugs [33].
Probiotics
What are probiotics?
Probiotic is a Latin-derived word with the meaning of
“for life” [35]. Fermented products which include cheese,
bread, wine, beer, and kefir were widely used for their
nutritional and therapeutic benefits long before the iden-
tification of probiotics [35]. Living microorganisms that
provide several beneficial impacts to their host in case of
proper amounts are called probiotics [36, 37]. This
broad definition comprises drugs containing probiotics,
conventional foods, medical foods, dietary supplements,
infant formula, animal feed, non-oral probiotics, and de-
fined microbial consortia [38]. The focus of earlier stud-
ies were nutritional roles of probiotics which have been
used as a food form or a dietary supplement [39]. How-
ever, recent probiotics research has concentrated on its
functions in the medical and therapeutic fields [40]. The
natural microbiota of intestine comprises the majority of
probiotics, which are particularly lactic acid bacteria, in-
cluding Enterococcus, Vagococcus, Weisella, Leuconostoc,
Lactococcus, Streptococcus, Tetragenococcus, Bifidobac-
terium, Carnobacterium, Oenococcus, Pedicoccus, Lacto-
bacillus, Escherichia coli, and Saccharomyces [41, 42].
Noteworthy, not all bacteria of the same species have
the same characteristics and may have different
effects on the organism. Besides, all strains are not
probiotic [43].
Applications of probiotics
Probiotics applications in the prevention or treatment of
various diseases have been studied in several investiga-
tions. Probiotics are involved in various processes of the
digestive system such as digestion, metabolism, innate
immunity of epithelial cells, eliminating pathogens, and
communication between brain and gut through their ad-
hesion to human intestines [44, 45]. Evidence has shown
the beneficial effects of gut microorganisms producing
nontoxic metabolites in different nutritional and clinical
aspects [46–48]. Probiotics and fermented non-digestible
food products, prebiotics, work together and have been
shown to have several beneficial characteristics such as
anti-pathogenic, anti-inflammation, antidiabetic, and
anti-obesity [49, 50]. Probiotics are also involved in im-
mune processes such as increasing antibody responses
and inhibiting the mononuclear cells proliferation [51,
52]. Probiotics have been used for a variety of gastro-
intestinal problems including irritable bowel syndrome,
constipation, ulcerative colitis, and necrotizing entero-
colitis [53–57]. Increasing anti-inflammatory cytokines
such as interleukin-10 (IL-10) and IL-12 and reducing
pro-inflammatory cytokines such as IL-1β and IL-6 are
anti-inflammatory activities of probiotics which have
been investigated in different diseases [58, 59]. Studies
indicated that probiotics can be helpful in autoimmune
diseases including rheumatoid arthritis, systemic lupus
erythematosus, and multiple sclerosis [58, 60–62]. Other
findings have also revealed that probiotics are beneficial
for high cholesterol levels in serum, allergy, vulvovaginal
candidiasis, HIV, and cancer [63–66].
Safety and side effects of probiotics
In general, probiotics are safe [67]. Although, in patients
who are immunocompromised or when someone is con-
sidered severely ill, precautions should be observed [67].
Rash, hiccups, nausea, constipation, and flatulence are
some of the most common adverse effects of probiotics
[67]. There are other probiotics side effects such as sys-
temic infections, damaging metabolic activities, and
transferring harmful genes such as resistance to anti-
microbial agents [68]. In some rare cases, using Lactoba-
cillus have led to the liver abscess, sepsis, and
endocarditis [67]. There is evidence indicating that
Bacillus subtilis can cause cholangitis, bacteremia, and
sepsis [69]. Also, it is reported that S. boulardii may lead
to fungal sepsis [70]. Altogether, probiotic-related risk of
infection is the same as infection risk of commensal bac-
terial strains, and it seems that the advantages of probio-
tics outweigh its risks [71].
Probiotics and cancer
One of the most prominent aspects in which probiotics
play a role is in the field of cancer. Probiotics act as a
double-edged sword in this field. Accumulative investi-
gations have revealed that microbiota can participate in
the process of carcinogenesis of many types of cancers,
including gynecological cancers. For instance in cervical
cancer, dysbiosis is approved to have influences on both
HPV infection by affecting HPV acquisition, clearance,
and persistence and host immune response by affecting
the levels of immune system proteins such as TGFβ1
[72]. Various studies have focused on the functions of
probiotics in diagnosis, prevention, or treatment of can-
cer. Besides their direct involvement in the mentioned
areas of cancers, probiotics can be used as an additional
agent in enhancing or modulating other diagnostic and
therapeutic methods. Kailasapathy et al. [73] have ex-
plained some underlying mechanisms by which probio-
tics may play their role as antitumor agents, such as
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activating the immune system of the host, changing
transit time and motility of the colon, suppressing pro-
carcinogens and carcinogens, inhibiting bacteria that are
involved in the transformation of pro-carcinogens to
carcinogens, and reducing intestinal pH [73]. Findings
demonstrate that probiotics make an impact on bio-
logical processes which are involved in cancer, including
apoptosis, oxidative stress, proliferation, inflammation,
and metastasis [74–77]. Long-time exposure to afla-
toxins, especially aflatoxin B1 has been related to a
higher risk of liver cancer development [78]. It is sug-
gested that probiotic supplements may be useful in pre-
venting liver cancer due to their ability to reduce the
aflatoxin exposure dose that is biologically effective [79].
Zonulin protein is involved in regulating intestinal per-
meability [80]. In colorectal cancer patients who
undergo colectomy, findings indicate that administering
probiotics perioperative results in a reduction in postop-
erative septicemia as well as zonulin concentrations in
serum [80]. In breast cancer, long-term administration
of probiotic strain Lactobacillus plantarum LS/07 has
shown immunomodulatory effects such as reducing
tumor necrosis factor (TNF)-α and increasing Cd4(+) T-
cells [81]. One of the common side effects of systemic
chemotherapy is diarrhea [82]. It has been revealed that
probiotic Clostridium butyricum can reduce
chemotherapy-induced diarrhea and systemic inflamma-
tory responses in lung cancer patients [83]. Altogether,
the role of probiotics in cancer is extensive and we will
provide a more detailed description of their functions in
cervical cancer.
Probiotics and cervical cancer
It was reported that probiotics can be efficient in differ-
ent gynecological diseases [84]. Herein, we look into
studies investigating how probiotics can be useful in the
prevention, diagnosis, and treatment of cervical cancer.
Roles of probiotics on cervical cancer cells
Wang et al. [85] have shown that Lactobacillus superna-
tants (LS), L. crispatus, L. jensenii, and L. gasseri, inhibit
the proliferation of Caski cells and cause some morpho-
logical alterations. Through incubating cells with LS, the
number of S phase cells increased significantly; mean-
while, G2/M phase cells decreased [85]. E6 and E7 are
two genes from eight genes that are encoded by HPV
[86]. These two genes encode the proteins that are
linked with p53 and pRB tumor suppressors and are re-
quired for conversion to malignancy [86]. LS treatment
results in a reduction in the expression of CDK2, cyclin
A, and HPV oncogenes (E6 and E7) [85]. Moreover, p21
expression was enhanced in LS-treated cells [85]. Lacto-
bacillus plantarum bacteria, which were isolated from
vaginal secretions of young adult and adolescent women,
are observed to have probiotic features and anticancer
activities against HeLa cervical cancer line [87]. Another
study on HeLa cell line revealed that human milk-
isolated Lactobacillus strains (Lactobacillus casei SR1,
Lactobacillus casei SR2, and Lactobacillus paracasei
SR4) have remarkable probiotic activities, including anti-
biotic susceptibility, antioxidant roles, low pH resistance,
and resistance to high levels of bile salts [88]. Further-
more, findings indicate that cell-free culture superna-
tants have anticancer activities, such as downregulating
BCL-2 and upregulating apoptotic genes (caspase3, cas-
pase8, caspase9, BAX, and BAD) [88]. Sungur et al. [89]
reported that human vagina-isolated L. gasseri strains,
G10 and H15, inhibits the HeLa cells proliferation.
Lactobacillus exopolysaccharides exert cytotoxic effects
on cancer cells and decrease their proliferation [90].
While lyophilized exopolysaccharides of L. gasseri strains
led to apoptosis in HeLa cells, G10 apoptosis induction
has related to Bax and Caspase3 upregulation [89].
Besides, strains of L.gasseri reduce TNF-α and increase
IL-10, which leads to their anti-inflammatory effect on
cervical cancer [89]. It is observed that treating HeLa
cells with supernatants of Lactobacillus rhamnosus and
lactobacillus crispatus reduces the expression of CASP3
gene as well as MMP2 and MMP9, which causes an in-
hibitory effect on metastasis [91]. Findings show that
Bifidobacterium adolescentis SPM1005-A exerts an anti-
viral activity in SiHa cervical cell line, which express
HPV type 16 and may prevent this cancer [92]. Treating
cells with this bacterium has been shown to reduce the
E6 and E7 oncogenes at mRNA and protein levels of E6
[92]. L. gasseri 3396 and L. cripatus 2743 are two pro-
biotic strains [93]. It is observed that L. cripatus 2743
has an inhibitory effect on the expression of E6 and E7
at the mRNA level [93]. Meanwhile, L. gasseri 3396 has
a smaller inhibitory impact on the E6 gene without any
significant effect on the E7 gene [93] (Table 1).
Probiotics effects on gastrointestinal problems of cervical
cancer patients
As we mentioned earlier, radiotherapy is an effective
method for treating cervical cancer patients [94]. How-
ever, radiotherapy has multiple side effects causing an
extra burden to patients such as nausea, vomiting, and
diarrhea [95, 96]. Radiotherapy-induced diarrhea is one
the most frequently occurred side effects, which can in-
volve up to 80% of patients and may lead to severe com-
plications [97, 98]. It is suggested that this side effect is
the result of lactose and bile acids malabsorption [45].
Moreover, it may be due to the alterations in the intes-
tinal flora and motility [45]. These events cause an im-
pairment in immune roles of the gastrointestinal tract as
well as its secretion and absorption [45].
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There are some investigations concerned with the
roles of probiotics in preventing or modulating the
gastrointestinal problems which cervical cancer pa-
tients face due to cancer itself or the treatments. It
is reported that administering a probiotic which con-
tains live Lactobacillus acidophilus LA-5 plus Bifido-
bacterium animalis subsp. lactis BB-12 leads to
reduced incidence of mild to moderate and severe
diarrhea in cervical cancer patients who undergo
beam pelvic radiotherapy [99]. In a study, a probiotic
drink has been used for patients with cervical carcin-
oma who received radiotherapy and weekly cisplatin.
Results showed that giving Lactobacillus casei DN-
114001 as a probiotic has a significant effect on
stool consistency. However, there was no reduction
in the incidence of diarrhea in patients who received
probiotic drink [100]. Another trial reported that
fewer patients who were assigned to VSL#3 had
radiation-induced diarrhea compared to the placebo
group. A higher percentage of patients in the pla-
cebo group experienced grade 3 or 4 diarrhea com-
pared to VSL#3 patients. Also, daily bowel
movements were lower in patients who receive
VSL#3 [101]. Therefore, probiotics can be considered
as safe and effective agents for reducing
radiotherapy-induced diarrhea in patients with cer-
vical cancer. Symbiotics are products consisting of
prebiotics and probiotics that include Lactobacilli,
Bacteroides, Bifidobasteria, and Eubacterium. This
product plays several beneficial roles including in-
activating carcinogens, maintaining the integrity of
intestine, immunomodulation, and anti-inflammatory
activities [102, 103]. Findings demonstrated that pa-
tients who were given symbiotic showed lower levels
of fecal calprotectin as well as less frequent and less
intense vomiting [104]. Thus, symbiotic supplemen-
tation may be also helpful in reducing gastrointes-
tinal adverse effects of cervical cancer patients
(Table 2).
Probiotics provide a better diagnosis of cervical cancer
Bacteria can be used as a diagnostic device through
engineering techniques that make the bacteria sense a
specific molecule in the human body and conse-
quently produce a signal [106]. For instance, Danino
et al. [107] developed a probiotic-based diagnostic
that is orally administered. They showed that using
Escherichia coli Nissle 1917 is a non-invasive ap-
proach for producing signals that are detectable in
urine; leading to the identification of liver metastasis.
Danino et al. [107] showed that by programming,
probiotics can be used for delivering gene circuits to
unhealthy tissue microenvironment. L. lactis has been
also used for detecting a molecule that is produced
by Vibrio cholera [108]. Through developing a diag-
nostic circuit in this bacteria, the color of the host’s
feces changes when there is an infection, which pro-
vides an early alert of cholera [108]. Thus, engineer-
ing may make it possible to use probiotics as a
diagnostic device in cervical cancer. Lactobacillus
rhamnosus GR-1 and Lactobacillus reuteri RC-14 are
two probiotic strains which have shown desirable ef-
fects on gynecological diseases [109, 110]. Evidence
suggests that using Lactobacillus rhamnosus GR-1
and Lactobacillus reuteri RC-14 along with anti-
infective agents leads to a reduction in false negative
and false positive results of cervical malignancies;
thus, cytological diagnoses are more reliable with this
method [111]. Compared to when using anti-infective
drugs alone, applying these probiotic strains provide a
higher percentage of vaginal microflora normalization
in patients who have vaginal infection [111]. A study
investigated the impacts of probiotic strains on the
quality of cervical smear and clearance of genital
high-risk human papilloma virus [112]. It is observed
that Lactobacillus rhamnosus GR-1 and Lactobacillus
reuteri RC-14 significantly reduced the rates of unsat-
isfactory and mildly abnormal cervical smears. How-
ever, they did not affect the clearance of HPV [112].
Table 1 Studies investigating probiotics effects on cervical cancer cells
Probiotic Cell line Findings References
supernatants of
L. crispatus, L. jensenii, and L. gasseri
Caski Inhibition of the viability by regulation of HPV oncogenes and cell cycle-related genes [85]
Vagina-isolated
L. plantarum
HeLa Suppression of proliferation and induction of apoptosis [87]
Milk-isolated
L. casei and L. paracasei
HeLa Induction of apoptosis [88]
Vagina-isolated L. gasseri HeLa Inflammation and proliferation were reduced and apoptosis was increased [89]
Supernatants of
L. rhamnosus
and L. crispatus
HeLa Proliferation and metastasis were suppressed [91]
Bifidobacterium adolescentis SPM1005-A SiHa Suppression of E6 and E7 oncogenes [92]
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Combination of probiotics with other cervical cancer
therapies
Cisplatin has been one of the most important chemo-
therapeutics in patients with advanced cervical cancer
[113]. It is reported that cisplatin pro-apoptotic and anti-
growth effects are enhanced by co-treatment with Lacto-
bacillus bacteria in mouse models with lung cancer
[114]. Co-treatment with Lactobacillus led to the upreg-
ulation of IFN-γ, PRF1, and GZMB; resulting in a better
anti-tumor response to cisplatin [114]. PD-L1 blockade
has shown a better anti-tumor activity in mice harbour-
ing unfavorable gut microbiota by orally administrating
Bifidobacterium probiotic. Also, it is observed that this
combined treatment prevented tumor growth [115]. A
study of 228 patients with cervical cancer at stage IIIB
demonstrated that combining LC9018, a response modi-
fier that is derived from heat-killed Lactobacillus casei
YIT9018, with radiation therapy would improve the out-
comes [116]. Okawa et al. concluded that patients who
received LC9018 as an adjuvant agent had a longer sur-
vival and relapse-free interval than patients who received
radiation therapy alone. Moreover, these patients
showed less severe radiation-induced leukopenia [116].
In a recent study, Negi et al. [117] provided a drug deliv-
ery approach in which probiotic strains were applied.
They concluded that the pessaries which contain cis-
platin and probiotic biomass can be a better therapeutic
method for cervical cancer since probiotic strains
showed favorable effects such as scavenging free radicals
[117]. In contrast, Kim et al. [118] reported that the
extract of L. casei showed no synergistic effects with
anti-cancer drugs to suppress the Hela and Caski cancer
cells growth. Although there are many studies on the
role of probiotics in cervical cancer, little is known about
their synergistic effect with other drugs of this cancer.
However, probiotics may be potential agents that can in-
crease the antitumor effects of other drugs [119].
Effects of probiotics on the therapeutic targets of cervical
cancer
While the majority of articles focus on the direct role of
probiotics on cervical cancer cells or their role in redu-
cing the side effects of other treatments, evidence from
other cancer types suggests that probiotics may affect
other drug targets of this cancer. However, studies in
this area are limited and more research is needed.
It is reported that miR-29a and miR-21 are the most
common downregulated and upregulated miRNAs, re-
spectively, involved in the progression of invasive cer-
vical cancer [120]. There some other dysregulated
miRNAs in cervical cancer, including miR-10a, miR-20b,
miR-106, miR-16 and miR-9 [120]. Moreover, exfoliated
cells of the cervix that are associated with cancer
progression present dysregulated miR-375, miR-125, and
miR-34a [120]. It is found that vaginal-isolated Lactoba-
cillus lactis leads to the downregulation of TLR-4, miR-
200b, and miR-21, which is associated with apoptosis
induction [121]. Also, it is observed that the probiotic
Escherichia coli Nissle 1917 restores the expression
levels of some miRNAs, including miR-143, miR-155,
Table 2 Studies concerned with the roles of probiotics in preventing or reducing the adverse effects of cervical cancer therapies on
gastrointestinal tract
Type of probiotics Dosage Duration of probiotic
consumption
Results References
L. acidophilus LA-5
plus Bifidobacterium
animalissubsp. Lactis
BB-12
One capsule containing 1.75 billion
lyophilized live bacteria t.i.d.
From the first day until the
end of radiotherapy
Severity and incidence of
radiotherapy-induced diarrhea
were reduced
[99]
L. acidophilus plus
bifidobacterium
bifidum
2 × 109 units of a L. acidophilus plus
bifidobacterium bifidum b.i.d.
Beginning 7 days before
starting radiotherapy and
continuing every day during
radiotherapy
Stool consistency was improved
and need for anti-diarrheal medi-
cation was reduced
[105]
L. casei DN-114001 96mL of a liquid yogurt containing
approximately 108 CFU/g of L. casei DN-
114001
t.i.d.
Beginning 7 days before
starting radiotherapy and
continuing every day during
radiotherapy
Stool consistency was improved
but there was no reduction in the
incidence of radiotherapy-induced
diarrhea
[100]
VSL#3 one sachet containing 450 billion/g of
bacteria, including four strains of lactobacilli,
three strains of bifidobacteria, and one strain
of Streptococcus salivarius t.i.d.
From the first day of
radiation therapy until the
end of the scheduled cycles
of radiotherapy
Daily bowel movements and
incidence of radiotherapy-induced
diarrhea were reduced
[101]
Sybmbotic symbiotic containing 1 × 107 (CFU)/g biogel
of L. acidophilus NCFM, Bifidobacterium lactis
Bi-07 1 × 106 CFU/g biogel, and blue agave
inulin t.i.d.
Seven weeks Fecal calprotectin and frequency
and intensity of vomiting were
reduced
[104]
Colony-forming unit, CFU; b.i.d., twice a day; t.i.d., three times a day
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and miR-375 [122]. MiR-21 is reported to have a signifi-
cantly higher level in the human umbilical vein endothe-
lial cell that were cultured in different conditions of
Lactobacillus acidophilus such as water extract, culture
media, culture-filtered and unfiltered supernatants. Fur-
thermore, cells treated with L. acidophilus culture
media have shown the highest miR-21 level compared
to cells treated with other conditions of L. acidophilus
Conversely, Escherichia coli lipopolysaccharide re-
sulted in a decrease in miR-21 levels compared to the
control group [123].
HPV infection triggers the activation of NF-κB that af-
fects both innate and adaptive immune responses. The
virus eliminates the inhibitory effects of the immune sys-
tem by downregulating NF-κB; resulting in a persistent
status of infection [124]. Then, NF-κB reactivates during
the transformation to cervical cancer. NF-κB leads to the
transcriptions of genes that are involved in proliferation
and metastasis as well as cell immortality and VEGF-
dependent angiogenesis [124]. Probiotics are capable of
inhibiting the inflammation through suppressing differ-
ent signaling pathways such as the nuclear factor-κB
(NF-κB) pathway. Besides, lipopolysaccharides binding
to the CD14 receptor can be inhibited by probiotics;
leading to a decrease in overall NF-κB activation as well
as the production of pro-inflammatory cytokines [125].
Findings show that anti-inflammatory Lactobacillus
plantarum NK3 and Bifidobacterium longum NK49 sup-
press the activation of NF-κB and the expression of
TNF-α in the mice vagina and uterus [126]. Lactoba-
cillus johnsonii, Bifidobacterium longum, Lactobacillus
plantarum, Lactobacillus delbruekii, and Lactobacillus
fermentum are also observed to inhibit NF-κB
activation [127–129].
Findings indicate that STAT3 has a potential role in
the development of cervical cancer [130, 131]. HPV
positive cervical cancer cells have a higher level of con-
stitutively activate STAT3 compared to HPV-negative
cells [132]. Moreover, Shukla et al. reported that STAT3
is associated with the conversion of precancerous
cervical lesions to cancer [132]. It is observed that pro-
inflammatory cytokine IL-6 mediate the autocrine
activation of STAT3 in HPV+ cervical cells [133]. Phos-
phorylation of STAT3 increases with both conditioned
media from HPV+ cervical cells and recombinant IL-6
[133]. Probiotic agent VSL#3 has chemopreventive roles
against the colitis-associated carcinogenesis. Evidence
has revealed that VSL#3 exerts its function through the
suppression of IL-6/STAT3 [134]. Zhou et al. [135] also
reported that exopolysaccharides from Lactobacillus
plantarum NCU116 promote the binding of STAT3 to
the promotor of occluding and ZO-1. Besides, treat-
ment with this exopolysaccharide results in STAT3
knockdown; leading to a reduction in the expressions
of occludin and ZO-1 [135]. On the other hand, it is
reported that Lactobacillus enhances the generation of
intestinal stem cells by activating STAT3 signaling
pathway [136].
Fig. 1 Representation of how probiotics are involved in the prevention, diagnosis, and treatment of cervical cancer
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Conclusions
Cervical cancer is one of the most important cancers
among women. Probiotics are beneficial in different can-
cers. Some studies have been focused on the effects of
the probiotic on cervical cancer (Fig. 1). Findings have
shown that probiotics have remarkable abilities which
may lead to the prevention or treatment of cervical can-
cer including induction of apoptosis, inhibiting prolifera-
tion, reducing inflammation, and suppressing metastasis.
Evidence suggests that concurrent use of probiotics with
other therapeutic drugs results in an improvement in
treatments. When combined with anti-infective drugs,
probiotics have been shown to provide a better diagnos-
tic method for cervical cancer patients. Besides, clinical
trials are indicating that administering probiotics have a
significant impact on gastrointestinal side effects which
are caused by cervical cancer therapies. However, more
research, especially clinical trials, should be done to
understand the precise effects of these anti-tumor
agents. Besides, the side effects of probiotics in cervical
cancer patients should also be carefully investigated.
Overall, probiotics appear to be potential anticancer
agents which can be used in the prevention and treat-
ment of cervical cancer.
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